Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Hua Medicine Completes Phase II Trial of Type 2 Diabetes Drug

publication date: Sep 22, 2016
Hua Medicine of Shanghai reports it has successfully completed a Phase II trial of HMS5552, a novel fourth-generation oral Glucokinase Activator (GKA) for type 2 diabetes. Hua in-licensed global rights to the candidate from Roche in 2011, its first program. The proof-of-concept trial, which enrolled 258 patients in 22 hospital centers across China, was led by Professor Dalong Zhu, President-elect of the Chinese Diabetes Society. Hua will release topline safety and efficacy results by mid-October. More details....

Stock Symbol: (SIX: ROG)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital